CEA (Carcinoembryonic antigen) is a type of glycoprotein attached to the cell membrane via glycosylphosphatidylinositol (GPI) anchor and stands for a set of highly related substance implicated in cell adhesion. It belongs to the immunoglobulin superfamily (IgSF) and there are two immunoglobulin domains including an N-terminal domain of 108 amino acids homologous to IgV-like and six domains homologous to the IgC2-like. The CAE gene family in humans is clustered on chromosome 19q and comprises 29 genes, 18 of which are commonly found. CEA is generally expressed in gastrointestinal tissue during embryonic development, but produced in very small amounts after birth. The serum level of it is not raised unless certain cancers tested. The CEA has become one of the most widely used tumor markers in clinical diagnosis and its main application is in gastrointestinal cancers, particularly in colorectal malignancy. GD2 is a kind of disialoganglioside expressed on tumor cells of neuroectodermal origin, including melanoma, glioma and neuroblastoma. Ganglioside GD2 is a sialic acid-containing glycosphingolipid involved in cell attachment to the extracellular matrix. Its expression is highly restricted in normal tissues, principally to the central nervous system, peripheral nerves, skin melanocytes, and mesenchymal stem cells of humans. The relatively specific tumor expression of GD2 makes it a suitable target for clinical therapy with monoclonal antibodies or artificial T cell receptors. Recently, GD2 has been proposed as a marker for some cancer cells and targeting ganglioside GD2 with immunotherapy has resulted in an improved outcome for patients suffering neuroblastoma.